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The inflammasome is a cytoplasmic protein complex that processes interleukins (IL)-1ȕ and IL-18, and 
drives a form of cell death known as proptosis. Oligomerization of this complex is actually the second 
step of activation, and a priming step must occur first. This involves transcriptional upregulation of pro-
IL-1ȕ, inflammasome sensor NLRPγ, or the non-canonical inflammasome sensor caspase-11. An 
additional aspect of priming is the post-translational modification of particular inflammasome 
constituents. Priming is typically accomplished in vitro using a microbial Toll-like receptor (TLR) ligand. 
However, it is now clear that inflammasomes are activated during the progression of sterile inflammatory 
diseases such as atherosclerosis, metabolic disease, and neuroinflammatory disorders. Therefore, it is time 
to consider the endogenous factors and mechanisms that may prime the inflammasome in these 
conditions.  
 
Innate Immunity and the Inflammasome 
The innate immune system is specialized to perform receptor-mediated surveillance for pathogen and/or 
tissue damage. Pattern recognition receptors are the first line of defense against invading microbes and 
are expressed in a variety of immune cells including macrophages, epithelial cells, dendritic cells, 
neutrophils, and adaptive immune cells. Some of these PRRs, such as the TLRs and C-type lectins 
(CTLs), are expressed on the cell surface and can be activated directly via external pathological signals 
known as pathogen-associated molecular patterns (PAMPs). PRRs are also triggered during sterile 
inflammatory diseases, suggesting a crucial role for danger signals that are not foreign but are instead 
host-derived. These are known as danger-associated molecular patterns (DAMPs). Both PAMPs and 
DAMPs can also make their way into the cell where they can trigger intracellular innate immune 
receptors directly, for example via recognition of DNA or RNA in the cytoplasm. Some cytosolic innate 
immune sensors are also activated indirectly as a result of a loss of homeostasis. These include NOD-like 
receptors (or NLRs) which assemble in the cytosol as inflammasomes, where they form a complex with 
the adaptor ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) [1]. 
Inflammasomes regulate the processing of the protease caspase-1, which in turn regulates the cleavage of 
cytokines IL-1ȕ and IL-18 from their respective precursors [2]. 
 
Of all the NLR inflammasomes, NLRP3 is the most widely studied [3, 4, 5]. The NLRP3 inflammasome is 
formed after indirect sensing of both non-sterile insults derived from pathogens (PAMPs) and sterile 
stressors (DAMPs). These range from bacterial products, mitochondrial DNA, viruses, and ATP to 
particulate matter such as crystals and amyloids [6, 7, 8]. Before a functional NLRP3 inflammasome can be 
formed, however, transcriptional and post-translational mechanisms must achieve a reasonable level of 
NLRP3 expression within the cell, and a suitable level of pro-IL-1ȕ must also accumulate – this is a 
process known as inflammasome priming, or ‘signal 1’ (Figure 1, Key Figure). This is distinct from 
cellular priming of B or T cells when they encounter antigen for the first time, which involves a process of 
differentiation and maturation. 
 
NLRP3 Inflammasome Priming: First Hit 
The functional regulation of an active inflammasome in a cell is a ‘two-hit’ process. The ‘first hit’ 
requires a non-activating stimulus to promote the transcriptional expression of key components of the 
inflammasome. Across species, the expression of both NLRP3 and IL-1ȕ is known to be transcriptionally 
regulated [9]. This is thought to prime the inflammasome before its activation by second stimuli (second 
hit). The ‘second hit’, either by the same and/or by additional stimuli, promotes the functional activity of 
the NLRP3 inflammasome [10]. Although most mammalian cells do not have a ready pool of IL-1ȕ, IL-18 
protein is expressed more constitutively [11], and thus may not have the same requirements for priming. 
Induction of active NLRP3 protein is also required to activate this inflammasome in most cell types; 
however, because as pathogen-associated factors that can accomplish this are well described, our interest 
is now diverted towards those host derived factors that may prime the inflammasome during sterile 
inflammatory diseases such as atherosclerosis, metabolic disease, and neuroinflammatory disorders. 
Indeed, many chronic inflammatory diseases have a clear role for NLRP3 activation, but the pathways 
that prime this functionality are not often discussed. Therefore, we now review endogenous factors that 
prime the NLRP3 inflammasome such as reactive oxygen species (ROS), oxidized low-density 
lipoprotein (oxLDL), hypoxia, complement, amyloids and misfolded proteins with a view to chronic and 
also monogenic inflammatory diseases that are sterile in nature. We also extend our discussion to the non-
canonical inflammasome which also has a similar requirement for priming as the NLRP3 inflammasome, 
albeit by different mechanisms. 
 
Mechanisms of NLRP3 Priming 
ROS Priming of the NLRP3 Inflammasome 
The majority of the literature to date has focused on the role of the mitochondria and mitochondrial 
reactive oxygen species (mROS) as signal 2 required for the generation of mature IL-1ȕ [12, 13, 14, 15]. An 
important distinction however is that activation of NLRP3 may actually be related to mitochondrial 
membrane potential [16, 17], while mROS production itself may in fact influence priming of NLRP3 [18]. 
For example, treatment of mouse macrophages with diphenyliodonium (DPI), a global mROS scavenger, 
was shown to impair lipopolysaccharide (LPS)-induced NLRP3 expression [5]. Furthermore, treatment 
with DPI decreased IL-1ȕ and IL-18 production following inflammasome activation, but only when DPI 
was added before the priming step (signal 1), suggesting that ROS – possibly of mitochondrial origin – 
could potentially block inflammasome activation by impairing the priming step required for NLRP3 
expression, and without affecting direct NLRP3 activation [5]. 
 
More recently, exposure of cells to hyperosmolarity has been demonstrated to induce NLRP3, ASC, pro-
caspase-1, and pro-IL-1ȕ expression and to promote the generation of ROS in human corneal epithelial 
cells [19]. These effects were abrogated when cells were treated with the antioxidant N-acetyl cysteine 
(NAC). The authors demonstrated that the induction of ROS following exposure to hyperosmotic stress 
preceded the effects on NLRP3, ASC, pro-caspase-1, and pro-IL-1ȕ expression, further supporting ROS 
as a mediator of NLRP3 priming in these cells. Moreover, a study performed on patients suffering from 
dry eye, a disease associated with tear film hyperosmolarity and inflammation, demonstrated that ocular 
surface samples from these patients displayed elevated NLRP3, ASC, pro-caspase-1, and pro-IL-1ȕ 
expression levels, as well as increased ROS levels compared to healthy controls [19]. This provides some 
evidence of a disease-relevant pathology where ROS may prime the NLRP3 inflammasome. 
 
Of note, as described in the sections below, ROS has emerged as a common effector mechanism shared 
by NLRP3 priming in response to hypoxia, metabolites, and several other conditions, suggesting that ROS 
may be a principal component required to prime the NLRP3 inflammasome in general. 
 
Hypoxia Priming of the NLRP3 Inflammasome 
Hypoxia is known to promote pro-IL-1ȕ production and has been implicated in the pathogenesis of 
several diseases including atherogenesis, where patient samples display increased NLRP3-derived 
IL-1ȕ production [20]. This study demonstrated that hypoxia could augment NLRP3 gene expression 
and protein levels in both LPS-treated and untreated human macrophages in vitro, and promoted 
pro-IL-1ȕ production by limiting its autophagic degradation[20]. 
 
In another study, animals subjected to renal ischemia/reperfusion (I/R) injury, which is known to 
induce hypoxia, displayed a significant upregulation of Nlrp3 and Pycard (ASC) gene expression 
compared to sham-operated control mice [21]. Nlrp3 RNA expression and protein levels were also 
increased in the brain following hypoxia–ischemia (HI) in a mouse model [22]. At earlier time 
points following HI, NLRP3 expression was detected in astrocytes in the hippocampus and the 
thalamus, and at later time points both astrocytes and microglia showed increased NLRP3 
expression [22]. Furthermore, hypoxic exposure was found to increase the levels of NLRP3, AIM2, 
and pro-IL-1ȕ in human prostate epithelial cells, in prostate cancer cell lines, and in THP-1 cells, 
and was targeted using an NF-κB inhibitor [23]. The authors suggested that such inflammasome 
priming might potentially contribute to prostatic chronic inflammation in human prostate tumors, 
but further validation is required. 
 
Of note, the hypoxia-inducible factor 1α (HIF-1α), a global transcription factor governing responses 
to hypoxia, is an NF-κB-dependent gene, and the gene encoding NF-κB itself contains a hypoxia-
response element (HRE) to which HIF-1α can bind to promote its expression [24]. Therefore, agents 
that activate NF-κB are likely to increase HIF-1α levels, and vice versa. Indeed, treatment of PC-3 
human prostate cancer cell lines with two hypoxic mimetics known to stabilize HIF-1α, 
dimethyloxalylglycine (DMOG) and cobalt chloride (CoCl2), boosted NLRP3 and pro-caspase-1 
levels [25]. The authors propose, but do not confirm, a role for ROS in such hypoxia-regulated 
priming. By contrast, CoCl2 was observed to have the opposite effect in mouse mixed glial cells [26]. 
Interestingly, both the human NLRP3 and PYCARD (ASC) genes are predicted to contain a HIF-1α 
binding site. This implies that hypoxia could be a key pathway priming the inflammasome, and that 
there might be significant synergy with NF-κB-activating factors in this regard. 
 
NLRP3 Priming by Metabolites 
The concept that metabolites can regulate NLRP3 is intriguing given their imbalance in several 
diseases related to inflammasome activation. While this idea is only in its infancy, several lines of 
evidence suggest that several metabolites can influence inflammatory processes. For instance, 
dimethyl fumarate (DMF), a cell-permeable ester of the Krebs cycle metabolite fumarate, has 
recently been approved as the front-line drug for the treatment of relapsing-remitting multiple 
sclerosis [27]. Dimethyl fumarate has been suggested to exert its beneficial effects largely by 
decreasing neuroinflammation [28]. It has also been shown to decrease ROS production in a mouse 
macrophage cell line [29], most likely as a consequence of its upregulation of antioxidants such as 
heme oxygenase-1, superoxide dismutase-2, and nuclear factor erythroid 2-related factor 2 (Nrf2), 
as well as decreasing IL-1ȕ (Il1b) mRNA expression, as shown in primary rat microglial cells [28]. 
Interestingly, DMF has been reported to be beneficial in the treatment of a mouse model of dextran 
sulfate sodium (DSS)-induced colitis by decreasing NLRP3 expression and activation in an Nrf2-
dependent manner [30]. In agreement with the in vivo data, pretreatment of inflammasome-activated 
human monocytic THP-1 cells with DMF decreased mRNA levels of NLRP3 and pro-IL-1ȕ [30]. 
This effect was also evident following inflammasome activation with alum and monosodium urate 
(MSU) crystals. The authors further demonstrated that DMF limited mitochondrial perturbations, 
including mROS production, mitochondrial membrane potential collapse, and mitochondrial DNA 
release, which occurred as a consequence of inflammasome activation. Nevertheless, whether DMF 
mediates its effects through this pathway to trigger NLRP3 priming specifically remains unclear. 
 
More generally, alterations in the glycolytic pathway have also been implicated in NLRP3 priming, 
as studied in mouse and human myeloid cells. For example, 2-deoxyglucose (2DG) – a potent 
inhibitor of glycolysis – has been shown to suppress LPS-induced pro-IL-1ȕ expression [31, 32, 33] 
and more recently has been found to limit ROS production in response to LPS and ATP, suggesting 
that its inhibitory effects may be at least partially ROS-dependent [32]. 2DG also inhibits NF-κB, 
and is thereby likely to impair NLRP3 expression and priming [34]. One study demonstrated that 
2DG only inhibited IL-1ȕ production when added before the LPS priming step, suggesting that it 
might limit pro-IL-1ȕ and NLRPγ priming [35]. By comparison, other work showed that addition of 
2DG after LPS, and before ATP, could affect NLRP3 inflammasome activation (signal 2) to 
generate mature IL-1ȕ [32]. Unexpectedly, in the latter study 2DG treatment had no effect on 
NLRP3 levels. This could suggest a role for post-translational regulation of NLRP3 priming, as 
discussed below. Consequently, it is clear from these studies that glucose metabolism is required 
for inflammasome function, but the data discriminating between NLRP3 priming and activation are 
controversial. 
 
The most definitive example of metabolite-mediated priming of NLRP3 stems from a recent 
publication. It was observed that the metabolite itaconate, the levels of which are highly 
upregulated in mouse M1 macrophages, limited the induction of NLRP3, ASC, and pro-IL-1ȕ in 
response to LPS, and subsequently impaired mature NLRP3-dependent IL-1ȕ production in 
vitro[36]. In addition, RNA sequencing analysis revealed that itaconate pretreatment decreased the 
expression of several LPS-induced genes linked to inflammasome priming, including Il1b, Il18, 
P2rx7, Casp1, and Pycard (which codes for ASC). Furthermore, in the same system, itaconate was 
shown to limit LPS-induced ROS production, providing mechanistic evidence for its inhibition of 
IL-1ȕ. This could help to explain why the same study also observed inhibition of a separate 
inflammasome nucleated by AIM2. Previously, overexpression of Irg1, the enzyme responsible for 
the generation of itaconate, was shown to increase the expression of Tnfaip3 (coding for A20), a 
negative regulator of NF-κB, in LPS-tolerized mouse macrophages [37]. This may represent another 
means by which itaconate could limit NF-κB activity to impair NLPRγ expression and 
inflammasome priming. 
 
Inflammasome Priming via Lipid Metabolism 
Products of lipid metabolism have previously been identified as activators of the inflammasome, 
and different laboratories have demonstrated that both palmitate and cholesterol crystals can 
activate the NLRP3 inflammasome [38, 39]. As described below, it has become clear that there is also 
a role for lipid metabolism in inflammasome priming, and that the lipidome of a cell can either 
facilitate or diminish priming of the inflammasome. 
 
Fatty acid synthesis is a major pathway in lipid metabolism, and the enzyme fatty acid synthase 
(FASN) produces palmitate from malonyl-CoA, acetyl-CoA, and NADPH. Recent work has 
demonstrated that functional FASN is essential for inflammasome priming in mouse peritoneal 
macrophages in response to LPS [40]. The authors demonstrated, through pharmacological and 
genetic approaches, that loss of function of FASN reduced NLRP3 induction in response to 
inflammatory stimuli, and that inhibition of FASN decreased IL-1ȕ and IL-18 levels in serum of 
mice during LPS challenge. Upstream of this, the mitochondrial uncoupling protein-2 (UCP2) was 
found to regulate FASN, and thus NLRP3 priming in mouse macrophages. Deletion of UCP2 
provided therapeutic benefit in a mouse model of sepsis involving cecal ligation and puncture 
(CLP). Downstream, FASN facilitated the inflammatory signal by promoting the phosphorylation 
of AKT; however, the kinase through which FASN might coordinate phosphorylation was not 
identified [40]. Activation of this kinase might occur through a regulatory lipid, downstream of 
FASN, or perhaps FASN might harbor an alternative novel enzymatic function. However, these 
questions remain unanswered. 
 
Cholesterol metabolism is another major pathway in lipid metabolism that is linked to 
inflammasome priming. Liver X receptor (LXR) transcription factors are activated in response to 
high levels of cholesterol to reduce cholesterol levels. However, in response to low cholesterol 
levels, sterol regulatory element binding proteins (SREBPs) are activated to increase transcription 
of the genes involved in fatty acid and cholesterol synthesis [41, 42]. Similarly, while the activation of 
LXRs reduces cholesterol and negatively regulates IL1Btranscription [43], activation of SREBPs not 
only increases cholesterol synthesis but also increases inflammasome priming, as shown in human 
umbilical vein endothelial cells (HUVEC) in vitro, and in mouse aortas in vivo[44]. In this study, 
oscillations in aortic blood flow over HUVECs not only promoted SREBP2 cleavage and activation 
but also promoted inflammasome priming by directly binding to the NLPR3 promoter. This 
demonstrated that proteins required for cholesterol synthesis might also have the capacity to 
directly increase the expression of inflammasome constituents. In a transgenic mouse model 
overexpressing SREBP2 on an apolipoprotein E knockout (Apoe−/−) background, the mice displayed 
increased atherosclerotic lesion size accompanied by increased expression of inflammasome 
components in the aortic arch [44]. This was associated with a disturbed flow pattern through the 
aortic arch, termed atheroprone flow, promoting activation of the overexpressed SREBP2 [44]. 
These data suggested that the initial trigger for atherosclerosis might be the shear force on the 
endothelium of the aorta activating SREBP2, and subsequently increasing priming of the 
inflammasome. Although these findings have not yet been replicated in macrophages or other 
immune cells, inflammasome priming might occur not only in response to pathogenic activators 
but, remarkably, also in response to physical stress. 
 
Inflammasome Priming via Complement 
The complement system is an integral part of the innate immune response (Box 1). Recent 
experimental evidence implicates the sublytic membrane attack complex (MAC) of complement in 
inflammation, modulating caspase-1 activation and IL-1ȕ secretion [45]. In particular, it has been 
demonstrated that sublytic MAC can trigger increased Ca2+ and, in turn, NLRP3 activation in 
primary human lung epithelial cells [45]. Moreover, MAC activation seems to be indispensable for 
NLRP3-mediated IL-1ȕ production because mice lacking complement protein C6, which have an 
impaired terminal MAC pathway, are not able to activate the inflammasome [46]. In addition, 
targeted deletion of complement component 9 (C9) leads to decreased IL-1ȕ production in a mouse 
model of LPS-induced inflammation, suggesting that C5b-9 might play a role in inflammasome 
priming or activation [47]. 
 
Recently, MAC has been suggested to provide both the priming and the activation signals for 
inflammasome activation because experiments indicated that MAC-mediated ‘bystander' damage 
could lead to NLRP3 activation in mouse macrophages [48]. Specifically, this study showed that 
phagocytosis of complement-opsonized particles could promote inflammasome activation by a 
novel ‘bystander' mechanism involving the transfer of MAC from the activating particle to a nearby 
cell. Of note, complement component C3a might function in this capacity because recent studies 
have implicated C3a in modulating IL-1ȕ production in human monocytes [49, 50]. Specifically, these 
studies found that C3a binding to the C3aR could drive IL-1ȕ production by triggering ERK1/β 
activation, leading to increased ATP efflux, and activating in turn the purinoceptor 7 (P2X7) as 
well as the NLRP3 inflammasome. The activation of this pathway synergized with TLR4 
stimulation, leading to enhanced type 17 T helper (Th17) cell responses; indeed, Th17 cell 
responses are relevant in pathogen clearance, and IL-17-mediated pathologies are associated with 
complement, as in the case of asthma [51]. 
 
Cholesterol crystals (CC) [52], MSU, and calcium phosphate crystals have all been found to trigger 
NLRP3 activation through lysosomal damage and ROS production [53]. The complement system has 
also been shown to recognize crystalline material, resulting in the production of C5a [54]. Recent 
studies have documented that C5a can trigger inflammasome activation in the presence of 
crystalline material [55, 56]. The first of these studies demonstrated that CC induced complement-
dependent inflammasome activation via C5a in human peripheral blood mononuclear cells [55]. The 
second study clearly showed that C5a could act as an endogenous priming signal for inflammasome 
activation because C5a alone was able to trigger inflammasome signal 1 upon induction of pro-IL-
1ȕ in primary human monocytes [56]. Binding of C5a to its receptor, C5aR, can also lead to calcium 
mobilization and triggering of intracellular signaling cascades such as phospholipase C [57], 
phospholipase D [58], PI3K [59, 60], Raf-1-mediated activation of MEK-1 [61], PI3K, MAP/ERK 
kinase, and Akt [62], potentially representing another priming mechanism of NLRP3. C5a is also 
able to prime human retinal pigment epithelial (RPE) cells for inflammasome activation in 
combination with lipofuscin[63], whose byproduct aggregates have been implicated in the 
pathogenesis of age-related macular degeneration (AMD). In a separate study, C5a was also shown 
to increase IL-1ȕ production via the mitogen activated protein (MAP) kinase pγ8 through C5aR1, 
but only in monocytes [64]. This study found opposite effects of C5a on mouse macrophages, with 
inhibition of IL-1ȕ production occurring independently of C5aR1. However, during LPS challenge 
of mice in vivo, C5aR1 deletion resulted in reduced IL-1ȕ levels in the circulation, confirming the 
importance of C5aR1 in IL-1ȕ induction, as shown in monocytes [64]. 
 
Post-Translational Modifications as Master Regulators of Transcription-Independent NLRP3 
Priming 
The idea of a rapid, transcriptional-independent, priming mechanism stems from the recent 
observation that inflammasome components undergo various different post-translational 
modifications. It was initially reported that inflammasome priming could occur as rapidly as 10 
minutes following LPS treatment in murine macrophages, an event that did not require protein 
synthesis [65]. This study found NLRP3 to be in an ubiquitinated, inactive state in resting 
macrophages, and demonstrated that mROS was responsible for triggering its deubiquitination 
following priming with LPS [65]. The role of deubiquitination in inflammasome activation has been 
later confirmed by other studies [66, 67]. NLRP3 was also found to be in an inactive polyubiquitinated 
state, and the deubiquitinase BRCC3 (BRCA1/BRCA2-containing complex subunit 3) was 
identified as a responsible mediator for activation of the inflammasome following signal 2 [66]. 
Interestingly, not all deubiquitinase inhibitors block priming-mediated deubiquitination, and 
BRCC3 has specifically been shown to have no effect on priming in these studies [66, 67]. The 
deubiquitinase responsible for NLRP3 inflammasome priming thus remains to be identified. In 
vivo, ubiquitination may be regulated in a tissue-specific manner, with mouse macrophages 
experiencing high levels of IL-10 that promote ubiquitinated-NLRP3 turnover, and, because the 
macrophages were obtained from colonic tissue, this pathway may have relevant implications for 
the pathogenesis of inflammatory bowel disease [68, 69]. 
 
Another post-translational modification associated with NLRP3 inflammasome transcription-
independent priming is phosphorylation. The extracellular signal-regulated kinase 1 (ERK-1) has 
been shown to be required in human monocytes for NLRP3 priming, while IL-1R-associated kinase 
(IRAK1) has been implicated in transcriptional-independent priming in murine macrophages [70, 71]. 
However, no phosphorylation site on NLRP3 has been associated with priming to date, and whether 
ERK and IRAK1 play a role in phosphorylating NLRP3 remains to be determined. Both these 
kinases − similarly to the NLRPγ deubiquitinase − depend on ROS production to exert their 
activities. A ROS scavenger has been found to block both IRAK1 and ERK effects on priming[70,71]. 
This emphasizes the importance of ROS in priming and the key role played by metabolism in 
immune cells driving inflammation. Lastly, it is interesting to speculate whether there might be a 
role for metabolism-derived post-translational modifications such as acetylation or malonylation in 
priming the NLRP3 inflammasome [72]. 
 
Priming the Inflammasome in Chronic Inflammatory Diseases 
Metabolic Disorders and Atherosclerosis 
The NLRP3 inflammasome is expressed in many metabolically relevant cell types such as 
macrophages [73], hepatocytes [74], and adipocytes [75]. The first study to demonstrate the relevance 
of the NLRP3 inflammasome in atherosclerosis showed that targeted disruption of individual 
components of the NLRP3 inflammasome (Nlrp3−/−, Asc−/− or Casp1−/−) significantly protected 
proatherogenic mice from disease [52]. Furthermore, transplantation of Nlrp3−/− bone marrow into 
low-density lipoprotein receptor knockout (Ldlr−/−) recipient mice was sufficient to reduce lesion 
sizes and decrease circulating levels of IL-1ȕ and IL-18 compared to mice receiving Nlrp3+/+ bone 
marrow [52]. Collectively, these studies indicate that the NLRP3 inflammasome, present in 
hematopoietic cells, is required for atherosclerotic plaque progression in hypercholesterolemic 
murine models. 
 
Increased circulating levels of low-density lipoprotein (LDL) are associated with atherosclerosis 
[76,77,78]
, obesity [79, 80], and insulin resistance [81]. Oxidized LDL is shown to provide both signal 1 
and signal 2 to prime and activate NLRP3 inflammasome in mouse models of atherosclerosis [52] 
and islet amyloid polypeptide (IAPP)-induced inflammasome activation in type 2 diabetes 
(T2D) [31]. Furthermore, scavenger receptor CD36 has been implicated in the regulation of oxLDL-
mediated NLRP3 inflammasome priming via TLR4/TLR6 in mouse macrophages and 
in Apoe−/− mouse models of atherosclerosis [82]. This provides evidence for a single DAMP being 
able to prime and activate the inflammasome to produce modest levels of IL-1ȕ, consistent with the 
low-grade but chronic inflammatory condition occurring during obesity and atherosclerosis. 
Ablation of NF-κB family kinase IKKi in the hyperlipidemic, proatherogenic Apoe−/− mouse model 
has reportedly led to increased NLRP3 inflammasome priming [83]. This work shows that induction 
of IKKi parallels priming of the NLRP3 inflammasome in PRR-activated mouse macrophages in 
vitro[83]. Once induced, it limits the chronicity of NLRP3 inflammasome priming and the 
subsequent inflammatory response in this proatherogenic and hyperlipidemic mouse model [83]. 
 
Given the heterogeneous cellular composition of atherosclerotic plaques, inflammasome regulation 
may not be limited to macrophages but could also occur in vascular smooth muscle cells (VSMCs). 
For example, expression of cytokines such as TNF-α in human atheroma plaques was shown not 
only to localize to macrophages but also to endothelial cells and VSMCs [84]. Indeed, cytokines 
such as TNFα can mediate inflammasome priming in human VSMCs by upregulating IL1B and 
NLRP3 gene expression [85]. TNF production from mouse macrophages, or by foam cells in the 
context of atherosclerosis, could therefore act in a paracrine or autocrine fashion to prime the 
NLRP3 inflammasome [86]. NLRP3 silencing in VSMCs can therefore decrease IL-1ȕ activation 
and secretion [85]. These studies suggest a role for the NLRP3 inflammasome in non-immune cells, 
and these might have a contributory effect in the progression of various chronic inflammatory 
pathologies. 
 
Obesity-Linked Disease 
Low-grade, chronic inflammation of adipose tissue is characterized by infiltration of 
proinflammatory macrophages, and both these features have been correlated with obesity-
associated insulin resistance and NLRP3 activation [39, 75]. Furthermore, macrophage switching from 
an anti-inflammatory (M2 macrophage) to proinflammatory (M1) phenotype occurs in white 
adipose tissue (WAT) as the adipose tissue becomes more metabolically dysregulated [87]. Obesity-
associated insulin resistance is characterized by increased expression of inflammasome-derived 
proinflammatory cytokines such as Il1b and Nlrp3 in mice [75, 88]. Activation of NLRP3 activity in 
adipose tissue macrophages (ATMs) during diet-induced obesity may mediate insulin resistance in 
adipocytes via IL-1ȕ secretion [39]. Secreted IL-1ȕ is reported to disrupt the insulin signaling 
pathway, reduce the expression of insulin receptor substrate 1 (IRS1), and lead to decreased insulin-
mediated glucose uptake resulting in insulin resistance [89, 90]. Secreted IL-1ȕ can also lead to its 
transcriptional autoregulation by a positive feedback loop via NF-κB pathways [91], leading to 
amplification of the priming signal. 
 
As mentioned above, TNF can also prime the NLRP3 inflammasome, and it has been shown that 
this is relevant for aged mice, which can develop increased NLRP3 expression in liver and adipose 
tissue, associated with peripheral insulin resistance and impaired glucose tolerance [92]. Overall, the 
priming and subsequent activation of the NLRP3 inflammasome in macrophages infiltrating 
different tissues during metabolic stress can result in increased inflammation and metabolic 
dysregulation in mouse models of metabolic dysregulation as well as in human disease [93, 94]. 
 
During progressive obesity, adipose tissue expansion can become limited, and the surplus spill-over 
of fat into the circulation and non-adipose organs during obesity has been suggested as a pathogenic 
mechanism [95]. This fat leakage may be scavenged by ATMs, resulting in ceramide synthesis. 
Ceramide has been reported to activate the inflammasome in mouse macrophages, resulting in 
increased inflammation in WAT during obesity [75]. Based on the observation that ceramides drive 
other proinflammatory pathways, such as NF-κB, this could be an endogenous priming agent for 
the inflammasome as well [96]. More evidence surrounds activation of the inflammasome by 
saturated fatty acids (SFAs) that are also liberated into the circulation during obesity [97]. These are 
thought to trigger TLR pathways in mice, and thus may also prime the NLRP3 inflammasome in 
the context of T2D [98], and could also play a role in non-alcoholic fatty liver disease (NAFLD) [99] 
as well as in fibrotic kidney disease. Although some reports did not find an effect of SFAs on 
NLRP3 priming [97], an activating Nlrp3 genetic mutation in mice that does not affect priming has 
been shown to lead to an additive effect with diets contributing to NAFLD [100]. This suggests that 
dietary intake with effects on metabolism could have a significant role in NLRP3 inflammasome 
priming. 
 
Neuroinflammation 
Amyloids and misfolded proteins are frequently associated with activation of the NLRP3 
inflammasome in vivo[101]. In some cases the misfolded protein itself may not only act as signal 2, 
to trigger NLRP3 oligomerization, but may also be able to act as signal 1, to prime NLRP3 and IL-
1ȕ expression. This is not necessarily a requirement, however, because complex biological 
processes are usually required to establish large quantities of amyloids or misfolded proteins in 
vivo, and these same processes can liberate other inflammatory molecules to prime the 
inflammasome. We highlight some examples of both settings, where inflammasome priming is 
either directly or indirectly associated with amyloids and misfolded proteins. 
 
One of the most profound in vivo effects of Nlrp3 deletion comes from a mouse model of 
Alzheimer’s disease. In this model familial forms of mutant amyloid precursor protein (APP) and 
presenilin 1 (PS1) are overexpressed in mice, and deletion of Nlrp3 has been shown to significantly 
improve object and spatial memory [102]. In vitro data using mouse macrophages suggest that 
amyloid can not only act as signal 2 to activate the inflammasome but may also engage with TLR4 
to trigger NF-κB and prime the inflammasome [103]. This is true not only for the Aȕ amyloid 
associated with Alzheimer’s disease but also for the IAPP amyloid that forms deposits in the 
pancreas during T2D [104], although this may proceed through TLR2/6 [105]. However, the effect of 
amyloids engaging TLRs has not been universally reported by all laboratories [31], hypothetically 
because of differences in the size of amyloid oligomers used in different experiments. Speculating 
further, in vivo it is possible that amyloidogenic species may bind to other DAMPs to facilitate 
activation of TLRs or of other NF-κB-dependent signaling pathways to prime NLRP3 
inflammasome activity. Another amyloid species, drusen, forms deposits in the eyes of individuals 
suffering from acute macular degeneration (AMD). These deposits are commonly associated with 
complement, which could act as a priming factor as discussed above. All amyloid-associated 
diseases also feature accumulation of advanced glycation end-products (AGEs) and, through their 
receptor RAGE, these could also prime the NLRP3 inflammasome during chronic amyloid-related 
pathology [106]. 
 
Although not an amyloid, mutant superoxide dismutase 1 (SOD1) is another misfolded protein that 
has been reported to trigger the NLRP3 inflammasome in familial amyotrophic lateral sclerosis [107]. 
In this case, as a cytoplasmic protein, there is less capacity for misfolded SOD1 to escape 
extracellularly and trigger TLR priming of the inflammasome in bystander cells. However, 
misfolded proteins can also lead to endoplasmic reticulum (ER) stress intracellularly [108], which 
could trigger signal 1 for NLRP3 activation [109], perhaps via damaged mitochondria and ROS [110]. 
S100A8/A9 proteins and HMGB1 are also molecules released by dead or dying cells downstream 
of an accumulation of misfolded proteins, and these also have the capacity to prime the 
inflammasome, as shown using peripheral blood mononuclear cells in vitro[111] and in mouse 
models [112]. This is also likely to be true for mutant α-synuclein protein, that is associated with 
Parkinson’s disease, which has been reported to engage TLRβ on human monocytes to prime the 
NLRP3 inflammasome [113]. 
 
Human pathology associated with amyloids and misfolded proteins frequently features elevated 
levels of serum AGE and S100A8/A9 proteins, rendering them attractive candidates for 
inflammasome priming during these, and perhaps other, chronic neurodegenerative conditions. 
Nevertheless, the field still needs to validate many of these findings, seeking to explain the 
discrepancies mentioned. 
 
Monogenic Autoinflammatory Disease 
Mutations that constitutively activate NLRP3 are one type of monogenic autoinflammatory 
disease. These periodic fever syndromes result in spontaneous ‘signal β' driving inflammasome 
activation, but still require priming to trigger the inflammatory pathology [114]. Nevertheless, this 
disease is dominantly inherited, and therefore priming must somehow be triggered during the lives 
of these patients, either from exposure to the environment, the microbiome, or endogenous 
DAMPs. Mice with similar mutations in NLRP3 display delayed disease progression when treated 
with antibiotics, suggesting not only that microbial PAMPs may contribute to priming in vivo but 
also that endogenous DAMPs might be potentially present because these mice do not resolve the 
disease [115]. 
 
Another autoinflammatory disorder where priming of the NLRP3 inflammasome may play a 
significant role is caused by loss-of-function mutations in the negative regulator of NF-κB Aβ0 
(HA20, haploinsufficiency of A20) [116]. Increased inflammation driven by constitutively active NF-
κB in patients does not seem to result in a significant increase in IL-1ȕ or IL-18 unless their cells 
are treated with LPS [116]. NLRP3 expression appears to be increased and therefore primed, as 
shown in the mouse model of A20 deficiency, where deletion of Nlrp3 can completely protect mice 
from disease [117]. Perhaps differences in mice and humans in this instance may reveal different 
priming mechanisms that are difficult to compare, with humans being exposed to a vast array of 
microbes relative to laboratory mice. 
 
These monogenic conditions highlight diseases that are not associated with infection, but 
nevertheless are NLRP3-dependent, and may require both microbial and endogenous priming. 
Priming of the Non-Canonical Inflammasome 
For decades, the protection of TLR4 mutant mice against LPS lethality was a cornerstone for innate 
immunity. Remarkably, the laboratories of Dixit and Miao independently rewrote this dogma and 
showed that, when mice were first primed to induce the non-canonical caspase-11 inflammasome, 
they were then susceptible to LPS lethality even in the absence of TLR4 [118, 119]. Caspase-11 can 
directly detect cytosolic LPS and, intriguingly, this also requires a priming step [120]. Whereas 
NLRP3 inflammasome priming for canonical caspase-1 inflammasomes is mediated by the 
TLR4/MyD88 axis, priming of non-canonical caspase-11 upon Escherichia coli or Citrobacter 
rodentium challenge is mediated by TLR4/TRIF [121, 122, 123]. Principally, this seems to be due to a 
requirement for interferon (IFN) signaling to induce caspase-11 expression (Figure 2). Hence, type 
I IFNs seem to play a prominent role in the regulation of caspase-11 transcription. Caspase-11 
expression is also upregulated by IFN-Ȗ [124]. This requires NF-κB and Stat1 binding to the caspase-
11 promoter [125]. There is also emerging literature suggesting that additional IFN-induced genes, 
guanylate-binding proteins (GBPs) and IRGB10, are required for LPS release from bacteria into the 
cytoplasm [126]. 
 
Surprisingly, despite the regulation of caspase-11 priming by IFN signaling, the potential of cellular 
metabolic processes and DAMPS being able to prime the non-canonical caspase-11 remain poorly 
studied. One study reported that ROS are able to induce caspase-11 during infection with C. 
rodentium[127]. A second study showed that, similarly to NLRP3, complement might also prime 
caspase-11 activity, although via a separate mechanism in which complement-related peptidase 
Cbp1 (carboxypeptidase B1) cleaves C3 to trigger C3aR [128]. Fas-associated protein with death 
domain (FADD) and caspase-8 in TLR4–NF-κB have also been proposed to prime both canonical 
and non-canonical inflammasomes [129]. This is intriguing, given the profound caspase-8-driven gut 
pathology that is associated with necroptosis of intestinal epithelial cells, which might connect 
the necroptotic and pyroptotic pathways implicated in IBD and sepsis in association with Gram-
negative bacteria [130]. 
 
One might speculate on how all of this information might translate to human caspases 4 and 5 
which are the homologs of murine caspase-11. In fact, most caspase-11 functionality appears to be 
encoded by caspase-4, which is constitutively expressed in myeloid cells [120]. Because caspase-5 is 
highly inducible, it may act more like caspase-11 with respect to priming; however, the specific 
mechanisms by which it is activated during a live infection remain to be elucidated [131]. The 
cellular distribution of caspase-4 and caspase-5 could also be a crucial determinant of their 
physiological functions. This information is important when considering how to intervene in the 
clinic for diseases associated with Gram-negative bacteria. Interestingly, small molecules with 
histone deacetylase activity appear to prevent caspase-11 expression and might be explored as 
putative therapeutic candidates [132]. One of these molecules, sodium butyrate, is known to bear 
anti-inflammatory activity in the regulation of the gut microbiota in mouse models [133], consistent 
with the newfound role of caspase-11 in the detection of cytoplasmic LPS. 
 
These studies highlight the importance of priming of the non-canonical inflammasome, bearing 
most relevance with regard to infections associated with Gram-negative bacteria. It is not yet clear 
which of these non-canonical inflammasomes are important in sterile inflammatory diseases; 
however, one interesting candidate may be metabolic disease. Indeed, oxPAPC (oxidized 
phospholipid) species may constitute a structural mimetic of LPS and directly bind to caspase-
11 [134]. More data are required to validate this in relevant metabolic models where oxPAPC may 
be pathogenic, and these might then highlight sterile inflammatory conditions for which priming of 
non-canonical inflammasomes is mediated by endogenous factors through IFN. 
 
Concluding Remarks 
Many inflammasome pathways play an important function in the host response to microbial 
pathogens, but dysregulation of the NLRP3 inflammasome is associated with many important 
diseases, and its role in infectious disease is, perhaps, less important than for some other 
inflammasome pathways. Pharmacological inhibition of dysregulated inflammasome activation 
may provide much-needed therapeutic benefit for patients suffering from chronic inflammatory 
diseases (see Outstanding Questions and Box 2). With numerous promising inhibitors of signal 2 
under development, the list of anti-inflammatory agents could be bolstered by ongoing work 
targeting pathways that trigger signal 1. Clear mechanistic insight on priming and the initial steps in 
inflammasome activation are likely to further our understanding of the pathogenic role of the 
inflammasome in various sterile inflammatory diseases. Furthermore, in this exciting field, such 
information may uncover clear opportunities for the development of novel therapeutic interventions 
to treat such conditions in the clinic. 
 
 
  
Trends 
NLRP3 inflammasome priming requires transcriptional upregulation of NLRP3 and pro-IL-1ȕ 
expression, together with post-translational modification of NLRP3 itself. 
Obesity and other chronic inflammatory states prime the NLRP3 inflammasome, and these constitute 
serious predisposing factors for inflammasome activation in sterile inflammatory disease. 
Microbial priming of the inflammasome could potentially drive crosstalk between the environment 
and the development of autoinflammatory disease. 
Inflammasome priming is not limited to immune cells, and can contribute significantly to overall 
pathology during chronic, low-grade inflammation. 
 
  
  
Outstanding Questions 
 
Is ROS the lynchpin of NLRP3 inflammasome priming? There are many paths towards priming the 
NLRP3 inflammasome, and many of them seem to converge on ROS. However, signal 2 of 
inflammasome activation is also implicated downstream of ROS. Therefore, delineating the separate 
pathways by which each of these processes occur will be challenging. 
Which post-translational modifications of NLRP3 or other inflammasomes are required for 
activation? A two-step mechanism of inflammasome activation is a sensible safety measure; 
consequently, will post-translational modification(s) constitute a priming requirement for 
inflammasomes other than NLRP3 that do not require transcriptional upregulation? Other than 
ubiquitination and phosphorylation, many options exist. 
Can NLRP3 inflammasome priming be targeted therapeutically? Targeting the priming step rather 
than the activation step may have broader effects on other inflammatory processes that could induce a 
favorable disease-modifying profile or unwanted susceptibilities to infection. 
Is non-canonical inflammasome priming crucial for human caspase-4 or caspase-5 in vivo? This may 
not be important during Gram-negative bacterial infections, where priming will certainly occur, but if 
caspase-4 or caspase-5 can be implicated in sterile inflammatory disease in will be interesting to 
identify the factors that prime this process. 
 
  
 Box 1 
The Complement System 
The complement system comprises at least 30 soluble proteins, cell-surface receptors, and regulators 
which can be sequentially activated by three distinct pathways – the classical, the lectin, and the 
alternative cascades. Once activated, complement has the capacity to kill pathogenic microorganisms 
by inserting the terminal complement complex C5b-9 into the surface of the target cell, forming a 
lytic pore that destroy the membrane integrity of the microorganism [135]. The terminal complement 
membrane attack complex (MAC) is formed by the activation of C5, followed by sequential activation 
of C6, C7, C8, and the polymerization of C9 forming the lytic pore [136]. Although MAC can form a 
lytic pore on the cell surface of host cells, most nucleated cells have efficient repair mechanisms to 
prevent host cell lysis via the use of regulators and ion pumps, and trigger an inflammatory 
response [137]. 
 
 
  
  
Box 2 
Clinician’s Corner 
Inhibition of Inflammasome Priming to Treat Inflammatory Diseases 
The inflammasome pathway represents a promising target for a variety of autoimmune and auto-
inflammatory diseases. There are many excellent recent reviews highlighting the discovery and novel 
mechanistic understanding of small-molecule inhibitors for NLRs and caspases, and the preclinical/ clinical 
impact of targeting the inflammasome products IL-1ȕ and IL-18 in disease [138, 139, 140, 141, 142]. 
 
Interfering with inflammasome priming may represent a novel approach for treating various pathologies 
including inflammatory, metabolic, and infectious diseases as well as cancer. Targeting the expression levels 
of NLRP3 could potentially lead to more attractive long-term therapeutic modalities and approaches such as 
microRNA- and ubiquitination-based techniques could be envisaged. 
 
Recent discoveries of several microRNAs (miRNAs) have shed light on the mechanistic regulation of 
NLRP3 expression levels through modulation of NLRP3 transcripts, and this might be therapeutically 
exploited to inhibit NLRP3 inflammasome activity. For example, miRNA-223 has been shown to suppress 
NLRPγ priming by binding to a conserved site in the γ′-untranslated region (UTR) of the NLRP3 transcript, 
thereby reducing downstream signaling [145, 146, 147]. In addition, inhibition of several other miRNAs involved 
in NLRP3 activation, miR115, miR133a-1, and miR-377, may be beneficial for suppression of NLRP3 
function [148, 149, 150]. 
 
Modulating post-translational modifications of NLRP3 could also lead to advanced therapies. For  
example, non-transcriptional priming associated with NLRP3 activation involves rapid deubiquitination of 
the protein [151]. The use of G5, a deubiquitinating enzyme (DUB) inhibitor (without known selectivity), or 
knockdown of BRCCA, a DUB regulating NLRP3 activation, has been shown to inhibit NLRP3 function in 
mouse macrophages [66]. Moreover, treatment with the DUB inhibitor PR619 has been shown to attenuate IL-
1ȕ production by BMDMs, which may involve enhanced association to HDAC6, another negative regulator 
of NLRP3 function [152]. In addition, heterobifunctional small molecules that simultaneously bind to a target 
protein and a ubiquitin ligase, PROTACs, can be used to enable ubiquitination and subsequent degradation 
of a target (reviewed in [153]). Consequently, it may be possible to enhance NLRP3 ubiquitination and 
promote its protein degradation via PROTACs, a putative strategy for targeted deletion of NLRP3. 
 
Various microbial ligands and inflammatory cytokines such as TNF-α and IL-1ȕ positively regulate 
inflammasome priming through the induction of NF-κB-mediated NLRP3 and pro-IL-1ȕ 
expression [91, 154, 155]. Inhibition of NF-κB signaling could thus represent one targeted approach to inhibit 
inflammasome activation. One molecule that may accomplish this, through effects on Aβ0 and TRAF6, is Ȗ-
tocotrienol, as demonstrated in a mouse model of T2D [156]. 
Glossary 
 
Apolipoprotein E knockout (Apoe−/−) mice  -  Mice with a genetic deficiency for ApoE that is required for normal 
catabolism of triglyceride-rich lipoproteins. 
 
Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC)  -  an adaptor protein used 
by many cytoplasmic PRRs to engage with caspase-1 in an inflammasome complex. 
 
Atherogenesis  -  the formation of abnormal lipid masses in the arterial wall that are associated with immune cell 
infiltration. 
 
Autophagic degradation  -  a cell-intrinsic mechanism to catabolize the endogenous components of a components. 
 
Danger-associated molecular patterns (DAMPs)  -  direct ligands for PRRs that are generated by dead or dying cells. 
 
Hypoxia  -  decreased oxygen availability. 
 
Inflammasome priming  -  increasing NLRP3 and pro-IL-1ȕ expression to a level that is sufficient for oligomerization 
and activation to proceed if triggered. 
Itaconatea  -  metabolite with antibacterial effects; produced in macrophages. 
 
Purinoceptor 7 (P2X7)  -  one of a family of cell-surface receptors triggered by ATP. 
 
Lipofuscin  -  pigment granule composed of lipids that accumulate in lysosomes. 
 
M1 macrophage  -  an ‘inflammatory’ macrophage subtype; it can be generated by stimulation with LPS and IFN-Ȗ. 
 
M2 macrophage  -  an ‘anti-inflammatory’ macrophage subtype (or ‘activated’); can be generated by stimulation with 
IL-4. 
 
Pathogen-associated molecular patterns (PAMPs)  -  direct ligands for PRRs that are of microbial origin, otherwise 
known as MAMPs. 
 
Pattern recognition receptors (PRRs)  -  receptors for ligands or signals that activate immune pathways. 
 
Monogenic autoinflammatory disease  -  an inherited condition associated with inflammatory manifestations that can 
be periodic in nature. 
 
Necroptotic and pyroptotic pathways  -  programmed cell death mediated by mixed-lineage kinase domain-like 
(MLKL; necroptosis) or caspase substrate gasdermin D (GSDMD; pyroptosis). 
 
Non-canonical inflammasome  -  the executioner caspase of the non-canonical inflammasome is caspase-11 
(mouse) or caspase-4/5 (human) rather than the canonical inflammasome (caspase-1). 
 
Scavenger receptor CD36  -  cell-surface import receptor for ligands such as low-density lipoprotein (LDL). 
 
Sterile inflammatory diseases  -  inflammatory conditions that are not associated with a pathogenic infection 
 
Sterol regulatory element binding proteins (SREBPs)  -  transcription factors that bind to DNA motifs commonly 
associated with enzymes regulating sterol biosynthesis. 
 
α-Synuclein  -  a protein found as insoluble deposits in the brains of individuals with Parkinson’s disease. 
 
Type 17 T helper (Th17) cell  -  inflammatory T helper cell defined by the production of IL-17. 
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Figure 1.  
Key Figure: Priming of the Canonical Inflammasome 
 
 
 
 
Several different receptors can prime IL-1ȕ and NLRPγ expression within the cell in response to endogenous 
DAMPs such as oxLDL, SFAs, amyloids, AGEs, and cholesterol crystals. Intracellular processes such as ER 
stress and metabolites such as itaconate also have pathways by which NLRP3 priming can proceed. Post-
transcriptional and autophagic regulation of the expression of different inflammasome constituents may also be 
an important consideration in priming. Abbreviations: AGE, advanced glycation end-product; DAMPS, danger-
associated molecular patterns; ER, endoplasmic reticulum; NAFLD, non-alcoholic fatty liver disease; oxLDL, 
oxidized low-density lipoprotein; P, phosphorylation; ROS, reactive oxygen species, SFAs, saturated fatty acids; 
Ub, ubiquitin; UPR, unfolded protein response. 
 
 
 
 
  
Figure 2.  
 
 
 
Priming of the Non-Canonical Inflammasome. Interferon production and complement activation induce the 
expression of caspases 11, 4, and 5 for non-canonical inflammasome activation. TRIF signaling also participates 
in priming and, together with Myd88 and reactive oxygen species (ROS), is important for the induction of pro-
IL-1ȕ which is necessary before it can be cleaved by caspases 11, 4, or 5. GBPs and IRGB10 are important for 
the liberation of lipopolysaccharide (LPS) from cytoplasmic vacuoles, while metabolic disorders may liberate 
oxidized phospholipid (oxPAPC) that can also directly bind to the non-canonical inflammasome sensors 
caspases 11, 4, and 5. Abbreviations: CASP, caspase; P, phosphorylation. 
